VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) will likely be releasing its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.3650) per share and revenue of $0.50 million for the quarter. Parties may review the information on the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.
VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) last posted its earnings results on Monday, June 15th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 133.02%. The company had revenue of $0.47 million during the quarter, compared to analyst estimates of $0.40 million. During the same quarter last year, the business posted ($1.67) EPS. On average, analysts expect VistaGen Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
VistaGen Therapeutics Trading Up 22.4%
Shares of NASDAQ VTGN opened at $0.30 on Wednesday. VistaGen Therapeutics has a twelve month low of $0.20 and a twelve month high of $5.14. The stock has a fifty day simple moving average of $0.42 and a 200-day simple moving average of $0.54. The stock has a market capitalization of $13.31 million, a PE ratio of -0.16 and a beta of 0.41.
Analysts Set New Price Targets
View Our Latest Analysis on VistaGen Therapeutics
Institutional Investors Weigh In On VistaGen Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Occudo Quantitative Strategies LP purchased a new stake in shares of VistaGen Therapeutics during the third quarter worth $152,000. Millennium Management LLC grew its stake in VistaGen Therapeutics by 853.0% during the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock worth $130,000 after purchasing an additional 176,369 shares in the last quarter. Bank of America Corp DE increased its holdings in VistaGen Therapeutics by 926.0% during the 3rd quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock worth $123,000 after purchasing an additional 31,279 shares during the period. Dimensional Fund Advisors LP raised its position in VistaGen Therapeutics by 123.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 151,874 shares of the company’s stock valued at $101,000 after purchasing an additional 83,857 shares in the last quarter. Finally, State Street Corp raised its position in VistaGen Therapeutics by 25.0% in the 4th quarter. State Street Corp now owns 121,114 shares of the company’s stock valued at $80,000 after purchasing an additional 24,256 shares in the last quarter. 78.39% of the stock is currently owned by institutional investors and hedge funds.
About VistaGen Therapeutics
VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.
The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.
Featured Stories
- Five stocks we like better than VistaGen Therapeutics
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
